Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Preclinical
September 9, 2022
World ADC San Diego
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Barnscher et al.
Preclinical
May 2, 2022 - May 6, 2022
PEGS
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Petersen et al.
Preclinical
March 31, 2022
World ADC London
TOPO1i ADC Platform: From Concept to Pipeline
Preclinical
April 10, 2021
AACR
Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
Bishop et al.
Preclinical
April 10, 2021
AACR
Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
Von Rossum et al.
Preclinical
April 10, 2021
AACR
ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
Heinkel et al.
Preclinical
April 14, 2018 - April 18, 2018
AACR
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
Hamblett et al.
